nach oben

Erschienen in:

15.03.2024 | Case Based Review

Tofacitinib therapy for severe pyoderma gangrenosum in a patient with enteropathic arthritis: a case-based review

verfasst von: Aydan Köken Avşar, Tuba Demirci Yıldırım, İsmail Sarı

Erschienen in: Rheumatology International | Ausgabe 10/2024

Einloggen, um Zugang zu erhalten

Abstract

Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis that is associated with systemic inflammatory conditions. Currently, there is no universally accepted standard therapy for PG, but immunosuppressive (IS) treatment seems essential. We report a patient here who was successfully treated with tofacitinib despite being PG-refractory to multiple anti-tumor necrosis factor alpha (anti-TNF) therapies and conventional IS. In addition, we performed a comprehensive review of all cases of PG treated with JAK inhibitors. We identified 27 cases treated with JAK inhibitors. Approximately 80% of the patients achieved complete recovery within a median of 12 weeks, even though 17 patients (63%) had received biologics before JAKinib treatment. Notably, this recovery could appear as early as 2 weeks. JAK inhibitors may prove useful in the future, particularly for treating immunosuppressive and steroid-resistant pyoderma gangrenosum, according to recent case reports.

Barbe M, Batra A, Golding S, Hammond O, Higgins JC, O’Connor A, Vlahovic TC (2021) Pyoderma gangrenosum: a literature review. Clin Podiatr Med Surg 38(4):577–588. https://doi.org/10.1016/j.cpm.2021.06.002CrossRefPubMed

Maronese CA, Pimentel MA, Li MM, Genovese G, Ortega-Loayza AG, Marzano AV (2022) Pyoderma gangrenosum: an updated literature review on established and emerging pharmacological treatments. Am J Clin Dermatol 23(5):615–634. https://doi.org/10.1007/s40257-022-00699-8CrossRefPubMedPubMedCentral

Flora A, Kozera E, Frew JW (2022) Pyoderma gangrenosum: a systematic review of the molecular characteristics of disease. Exp Dermatol 31(4):498–515. https://doi.org/10.1111/exd.14534CrossRefPubMed

George C, Deroide F, Rustin M (2019) Pyoderma gangrenosum—a guide to diagnosis and management. Clin Med 19(3):224–228. https://doi.org/10.7861/clinmedicine.19-3-224CrossRef

Welsch K, Holstein J, Laurence A, Ghoreschi K (2017) Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors. Eur J Immunol 47(7):1096–1107. https://doi.org/10.1002/eji.201646680CrossRefPubMed

Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31(11):1409–1417. https://doi.org/10.1007/s00296-011-1999-3CrossRefPubMed

Kim HS, Kwon JE, Park YJ (2023) Atezolizumab plus bevacizumab-induced recalcitrant pyoderma gangrenosum treated with baricitinib: a case report. Acta Derm Venereol 103:adv9646. https://doi.org/10.2340/actadv.v103.9646CrossRefPubMed

Scheinberg M, Machado LA, Castro LGM, Ferreira SB, Michalany N (2021) Successful treatment of ulcerated pyoderma gangrenosum with baricitinib, a novel JAK inhibitor. J Transl Autoimmun 4:100099. https://doi.org/10.1016/j.jtauto.2021.100099CrossRefPubMedPubMedCentral

Castro LGM (2023) JAK inhibitors: a novel, safe, and efficacious therapy for pyoderma gangrenosum. Int J Dermatol 62(8):1088–1093. https://doi.org/10.1111/ijd.16676CrossRefPubMed

10.

Sathyanarayana VA, Roy D, Nagaraju B, Rao VKR (2023) Tofacitinib in pyoderma gangrenosum—a case series. Int J Rheum Dis. https://doi.org/10.1111/1756-185X.14810CrossRefPubMed

11.

Gregory MH, Ciorba MA, Deepak P, Christophi GP (2019) Successful treatment of pyoderma gangrenosum with concomitant tofacitinib and infliximab. Inflamm Bowel Dis 25(7):e87–e88. https://doi.org/10.1093/ibd/izz015CrossRefPubMed

12.

Salmón Olavarría P, Rubio Iturria S, Nantes Castillejo Ó (2021) Tofacitinib, a useful option for the treatment of pyoderma gangrenosum in an ulcerative colitis patient. Rev Esp Enferm Dig 113(10):733–734. https://doi.org/10.17235/reed.2021.7977/2021CrossRefPubMed

13.

Sedano R, Jairath V (2021) Tofacitinib for the treatment of three immune-mediated conditions in one patient: ulcerative colitis, pyoderma gangrenosum, and alopecia areata. Inflamm Bowel Dis 27(5):e65. https://doi.org/10.1093/ibd/izab005CrossRefPubMed

14.

Van Eycken L, Dens AC, de Vlam K, Neerinckx B, De Haes P (2023) Resolution of therapy-resistant pyoderma gangrenosum with upadacitinib. JAAD Case Rep 37:89–91. https://doi.org/10.1016/j.jdcr.2023.05.016CrossRefPubMedPubMedCentral

15.

Dos Santos MR, Ianhez M, Ribeiro BN, de Queiroz BB, Miot HA (2023) Refractory pyoderma gangrenosum associated with rheumatoid arthritis successfully treated with upadacitinib. Comments on: “JAK inhibitors: a novel, safe, and efficacious therapy for pyoderma gangrenosum.” Int J Dermatol 62(11):e595–e598. https://doi.org/10.1111/ijd.16791CrossRefPubMed

16.

Rahbar Kooybaran N, Korsten P, Schön MP, Mössner R (2022) Ansprechen eines mit rheumatoider arthritis assoziierten pyoderma gangraenosum auf den JAK1-inhibitor upadacitinib. J Dtsch Dermatol Ges 20(4):522–524. https://doi.org/10.1111/ddg.14716_gCrossRefPubMed

17.

Shanmugam VK, McNish S, Shara N, Hubley KJ, Kallakury B, Dunning DM, Attinger CE, Steinberg JS (2013) Chronic leg ulceration associated with polycythemia vera responding to ruxolitinib (Jakafi(®)). J Foot Ankle Surg 52(6):781–785. https://doi.org/10.1053/j.jfas.2013.07.003CrossRefPubMedPubMedCentral

18.

Nasifoglu S, Heinrich B, Welzel J (2018) Successful therapy for pyoderma gangrenosum with a Janus kinase 2 inhibitor. Br J Dermatol 179(2):504–505. https://doi.org/10.1111/bjd.16468CrossRefPubMed

19.

Choi AW, Abuav R, Rabizadeh SM, Ansari R, Marsch AF (2020) Recalcitrant and severe pyoderma gangrenosum attributable to levamisole-adulterated cocaine and treated successfully with oral tofacitinib. JAAD Case Rep 6(9):939–941. https://doi.org/10.1016/j.jdcr.2020.07.035CrossRefPubMedPubMedCentral

20.

Kochar B, Herfarth N, Mamie C, Navarini AA, Scharl M, Herfarth HH (2019) Tofacitinib for the treatment of pyoderma gangrenosum. Clin Gastroenterol Hepatol 17(5):991–993. https://doi.org/10.1016/j.cgh.2018.10.047CrossRefPubMed

21.

Sitaru S, Biedermann T, Lauffer F (2022) Successful treatment of pyoderma gangrenosum with Janus kinase 1/2 inhibition. JEADV Clin Pract 1(4):420–423. https://doi.org/10.1002/jvc2.62CrossRef

22.

Bhowmick K, Roongta R, Dey S, Dey S, Mondal S, Sinhamahapatra P, Ghosh P, Ghosh B (2023) Refractory Takayasu arteritis with recurrent pyoderma gangrenosum: a therapeutic challenge with case-based review. Clin Rheumatol 42(5):1469–1477. https://doi.org/10.1007/s10067-023-06506-xCrossRefPubMed

23.

Orfaly VE, Kovalenko I, Tolkachjov SN, Ortega-Loayza AG, Nunley JR (2021) Tofacitinib for the treatment of refractory pyoderma gangrenosum. Clin Exp Dermatol 46(6):1082–1085. https://doi.org/10.1111/ced.14683CrossRefPubMed

24.

Ahronowitz I, Harp J, Shinkai K (2012) Etiology and management of pyoderma gangrenosum: a comprehensive review. Am J Clin Dermatol 13(3):191–211. https://doi.org/10.2165/11595240-000000000-00000CrossRefPubMed

25.

Ormerod AD, Thomas KS, Craig FE, Mitchell E, Greenlaw N, Norrie J, Mason JM, Walton S, Johnston GA, Williams HC, UK Dermatology Clinical Trials Network’s STOP GAP Team (2015) Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial. BMJ 350:h2958. https://doi.org/10.1136/bmj.h2958CrossRefPubMedPubMedCentral

26.

Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, Griffiths CE, Forbes A, Greenwood R, Probert CS (2006) Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 55(4):505–509. https://doi.org/10.1136/gut.2005.074815CrossRefPubMedPubMedCentral

27.

Dissemond J, Marzano AV, Hampton PJ, Ortega-Loayza AG (2023) Pyoderma gangrenosum: treatment options. Drugs 83(14):1255–1267. https://doi.org/10.1007/s40265-023-01931-3CrossRefPubMedPubMedCentral

28.

Ben Abdallah H, Fogh K, Bech R (2019) Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: a semi-systematic review. Int Wound J 16(2):511–521. https://doi.org/10.1111/iwj.13067CrossRefPubMedPubMedCentral

29.

Ben Abdallah H, Fogh K, Vestergaard C, Bech R (2022) Pyoderma gangrenosum and interleukin inhibitors: a semi-systematic review. Dermatology 238(4):785–792. https://doi.org/10.1159/000519320CrossRefPubMed

30.

Ahn C, Negus D, Huang W (2018) Pyoderma gangrenosum: a review of pathogenesis and treatment. Expert Rev Clin Immunol 14(3):225–233. https://doi.org/10.1080/1744666X.2018.1438269CrossRefPubMed

31.

Alves de Medeiros AK, Speeckaert R, Desmet E, Van Gele M, De Schepper S, Lambert J (2016) JAK3 as an emerging target for topical treatment of inflammatory skin diseases. PLoS ONE 11(10):e0164080. https://doi.org/10.1371/journal.pone.0164080CrossRefPubMedPubMedCentral

32.

Demirci Yildirim T, Kahraman A, Köken Avşar A, Onen F, Akar S, Sari İ (2023) Quantitative analysis of JAK/STAT signaling pathway in patients of inflammatory skin disorders. Rheumatol Int. https://doi.org/10.1007/s00296-023-05418-yCrossRefPubMed

33.

Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Thirunavukkarasu K, DeMasi R, Geier J, Kwok K, Wang L, Riese R, Wollenhaupt J (2017) Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis 76(7):1253–1262. https://doi.org/10.1136/annrheumdis-2016-210457CrossRefPubMed

Titel: Tofacitinib therapy for severe pyoderma gangrenosum in a patient with enteropathic arthritis: a case-based review
verfasst von: Aydan Köken Avşar
Tuba Demirci Yıldırım
İsmail Sarı
Publikationsdatum: 15.03.2024
Verlag: Springer Berlin Heidelberg
Erschienen in: Rheumatology International / Ausgabe 10/2024
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-024-05560-1

Exploring TNFi drug-levels and anti-drug antibodies during tapering among patients with inflammatory arthritis: secondary analyses from the randomised BIODOPT trial

Open Access
Clinical Trials

Association of serum and synovial adipokines (chemerin and resistin) with inflammatory markers and ultrasonographic evaluation scores in patients with knee joint osteoarthritis- a pilot study

Observational Research

Exploring pulmonary involvement in newly diagnosed rheumatoid arthritis, and psoriatic arthritis: a single center study

Open Access
Observational Research

Sexual dysfunction and self-perceived sexual health in patients with rheumatoid arthritis and systemic lupus erythematosus: results from a cross-sectional survey

Patient Opinion

Heart involvement in patients with systemic sclerosis—what have we learned about it in the last 5 years

Open Access
Review

Bilateral juvenile temporal arteritis: a case-based review

Open Access
Case Based Review

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

ctDNA erkennt minimale Resterkrankung beim Melanom

25.04.2025
Tumormarker
Nachrichten

Die Diagnose einer minimalen Resterkrankung mithilfe zirkulierender Tumor-DNA könnte (ctDNA) auch das Management von Patientinnen und Patienten mit Melanomen im Stadium III bereichern, wie Ergebnisse einer Studie nahelegen – auch wenn die Methode noch nicht perfekt funktioniert.

Lipidtherapie im Praxisalltag: Noch viel Spielraum für Verbesserung

25.04.2025
DGK-Jahrestagung 2025
Kongressbericht

Wie steht es um die Behandlung von Dyslipidämien bei Risikopatienten mit atherosklerotischer Gefäßerkrankung in Deutschland? Eine Bestandsaufnahme dazu liefert das bei der DGK-Tagung 2025 vorgestellte Forschungsprojekt LipidSnapshot.

Lohnt sich die Karotis-Revaskularisation?

25.04.2025
Karotisstenose
Nachrichten

Die medikamentöse Therapie für Menschen mit Karotisstenosen hat sich in den vergangenen Dekaden verbessert. Braucht es also noch einen invasiven Eingriff zur Revaskularisation der Halsschlagader bei geringem bis moderatem Risiko für einen ipsilateralen Schlaganfall?

Höhere Dosis von Dexamethason senkt Überlebenschancen

25.04.2025
Zerebrale Metastasen
Nachrichten

Personen mit Hirnmetastasen, die perioperativ höhere kumulative Dosen von Dexamethason erhalten, haben eine schlechtere Prognose. Um die Ergebnisse zu verbessern, bedarf es strengerer Dosierungsschemata.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Jetzt 10 CME-Punkte sammeln

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Tofacitinib therapy for severe pyoderma gangrenosum in a patient with enteropathic arthritis: a case-based review

Abstract

Weitere Artikel der Ausgabe 10/2024

Exploring TNFi drug-levels and anti-drug antibodies during tapering among patients with inflammatory arthritis: secondary analyses from the randomised BIODOPT trial

Association of serum and synovial adipokines (chemerin and resistin) with inflammatory markers and ultrasonographic evaluation scores in patients with knee joint osteoarthritis- a pilot study

Exploring pulmonary involvement in newly diagnosed rheumatoid arthritis, and psoriatic arthritis: a single center study

Sexual dysfunction and self-perceived sexual health in patients with rheumatoid arthritis and systemic lupus erythematosus: results from a cross-sectional survey

Heart involvement in patients with systemic sclerosis—what have we learned about it in the last 5 years

Bilateral juvenile temporal arteritis: a case-based review

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Neu im Fachgebiet Innere Medizin

ctDNA erkennt minimale Resterkrankung beim Melanom

Lipidtherapie im Praxisalltag: Noch viel Spielraum für Verbesserung

Lohnt sich die Karotis-Revaskularisation?

Höhere Dosis von Dexamethason senkt Überlebenschancen

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten